Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business And Finance In Brief

Executive Summary

Merck and Schering-Plough - it's official: The ribbon is wrapped around the merger between the two companies. Shareholders of both approved the deal Aug. 7

You may also be interested in...



Chew On This: FDA OK's King's Tamper-Resistant Morphine, Embeda

Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.

Biovail Locks Up Global Rights To Xenazine With Cambridge Deal

The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.

Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel